120 related articles for article (PubMed ID: 34263694)
1. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis.
Al Saleh AS; Visram A; Parmar H; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Go RS; Gonsalves WI; Kourelis TV; Hayman SR; Kapoor P; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
Leuk Lymphoma; 2021 Dec; 62(12):3011-3018. PubMed ID: 34263694
[TBL] [Abstract][Full Text] [Related]
2. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.
Al Saleh AS; Ebraheem MS; Sidiqi MH; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Blood Cancer J; 2022 Apr; 12(4):59. PubMed ID: 35410992
[TBL] [Abstract][Full Text] [Related]
3. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
Hari P; Blazer M; Raju A; Farrelly E; Labotka R; Skacel T; Romanus D
Expert Rev Hematol; 2019 Jan; 12(1):71-79. PubMed ID: 30513016
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
[TBL] [Abstract][Full Text] [Related]
5. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
Chen Y; Lairson DR; Chan W; Du XL
Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of bortezomib-based therapy in myeloma.
Djebbari F; Srinivasan A; Vallance G; Moore S; Kothari J; Ramasamy K
PLoS One; 2018; 13(12):e0208920. PubMed ID: 30540831
[TBL] [Abstract][Full Text] [Related]
7. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
9. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
13. Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.
Kumar S; Williamson M; Ogbu U; Surinach A; Arndorfer S; Hong WJ
Cancer Med; 2021 Sep; 10(17):5866-5877. PubMed ID: 34402201
[TBL] [Abstract][Full Text] [Related]
14. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
15. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
[TBL] [Abstract][Full Text] [Related]
16. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
D'Agostino M; De Paoli L; Conticello C; Offidani M; Ria R; Petrucci MT; Spada S; Marcatti M; Catalano L; Gilestro M; Guglielmelli T; Baldini L; Gamberi B; Rizzi R; De Sabbata G; Di Renzo N; Patriarca F; Pezzatti S; Siniscalchi A; Ribolla R; Palumbo A; Montefusco V; Nagler A; Boccadoro M; Gay F
Crit Rev Oncol Hematol; 2018 Dec; 132():9-16. PubMed ID: 30447931
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Usmani S; Ahmadi T; Ng Y; Lam A; Desai A; Potluri R; Mehra M
Oncologist; 2016 Nov; 21(11):1355-1361. PubMed ID: 27486203
[TBL] [Abstract][Full Text] [Related]
18. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Richardson PG; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Corrado C; Binlich F; San-Miguel JF
Blood; 2016 Feb; 127(6):713-21. PubMed ID: 26631116
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma.
Toor SH; Satti TM; Iftikhar R; Mahmood SK; Shamshad GU; Rehman JU
J Coll Physicians Surg Pak; 2020 May; 30(5):527-531. PubMed ID: 32580853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
